Zhu Feiqi, Li Chunrong, Chu Fengna, Tian Xiaoping, Zhu Jie
Cognitive Impairment Ward of Neurology Department, The Third Affiliated Hospital of Shenzhen University Medical College, Shenzhen, China.
Department of Neurology, Neuroscience Center, The First Hospital of Jilin University, Changchun, China.
Front Aging Neurosci. 2020 Oct 6;12:544235. doi: 10.3389/fnagi.2020.544235. eCollection 2020.
Alzheimer's disease (AD) is commonly an age-associated dementia with neurodegeneration. The pathogenesis of AD is complex and still remains unclear. The inflammation, amyloid β (Aβ), and neurofibrillary tangles as well misfolded tau protein in the brain may contribute to the occurrence and development of AD. Compared with tau protein, Aβ is less toxic. So far, all efforts made in the treatments of AD with targeting these pathogenic factors were unsuccessful over the past decades. Recently, many studies demonstrated that changes of the intestinal environment and gut microbiota gut-brain axis pathway can cause neurological disorders, such as AD, which may be involved in the pathogenesis of AD. Thus, remodeling the gut microbiota by various ways to maintain their balance might be a novel therapeutic strategy for AD. In the review article, we analyzed the characteristics of gut microbiota and its dysbiosis in AD and its animal models and investigated the possibility of targeting the gut microbiota in the treatment of the patients with AD in the future.
阿尔茨海默病（AD）通常是一种与年龄相关的神经退行性痴呆。AD的发病机制复杂，目前仍不清楚。大脑中的炎症、淀粉样β蛋白（Aβ）、神经纤维缠结以及错误折叠的tau蛋白可能与AD的发生和发展有关。与tau蛋白相比，Aβ的毒性较小。在过去几十年里，针对这些致病因素进行AD治疗的所有努力均未成功。最近，许多研究表明，肠道环境和肠道微生物群的变化以及肠-脑轴途径可导致神经紊乱，如AD，这可能参与了AD的发病机制。因此，通过各种方式重塑肠道微生物群以维持其平衡可能是AD的一种新型治疗策略。在这篇综述文章中，我们分析了AD及其动物模型中肠道微生物群的特征及其失调情况，并探讨了未来针对肠道微生物群治疗AD患者的可能性。
